Endo International plc (OTC: ENDPQ), an American-Irish specialty pharmaceutical company, announced on Thursday that one of its operating companies, Par Pharmaceutical, Inc, has started shipping colchicine 0.6mg capsules, a generic version of Hikma's MITIGARE.
The product is intended for prophylaxis of gout flares in adults. It is the first generic colchicine capsule approved by the US Food and Drug Administration.
Scott Sims, Endo senior vice president and general manager, Injectable Solutions & Generics, said, 'We are pleased to offer this high-quality, affordable medication. As a reliable supplier of generic products, we take pride in providing choices to appropriate patients.'
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey